SCHEMBL4241050

SCHEMBL4241050

CCCNCc1cc(C(F)(F)F)ccc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 5/20 0.45
SLC6A4 P31645 4/20 0.45
HTR2A P28223 4/20 0.45
TMEM97 Q5BJF2 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
TP53 P04637 1/20 0.40
SLC6A2 P23975 1/20 0.40
P2RX7 Q99572 1/20 0.39
EPHX2 P34913 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
ALDH1A1 P00352 3/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HTR1A P08908 1/20 0.37
HTR1D P28221 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4236331 0.87 KCNH2 (0.48) KCNH2SLC6A4HTR2ATMEM97MEN1
SCHEMBL4239870 0.86 KCNH2 (0.43) KCNH2SLC6A4HTR2ATMEM97MEN1
SCHEMBL4240375 0.84 ALOX5AP (0.46) KCNH2SLC6A4HTR2AKMT2ATP53
SCHEMBL4244859 0.80 SLC6A4 (0.63) KCNH2SLC6A4HTR2ATMEM97TP53
SCHEMBL4242538 0.79 KCNH2 (0.46) KCNH2SLC6A4HTR2ATMEM97MEN1
SCHEMBL5675704 0.79 MEN1 (0.41) KCNH2SLC6A4HTR2AMEN1KMT2A
SCHEMBL2565147 0.78 CTSS (0.47) KCNH2SLC6A4HTR2ATMEM97MEN1
SCHEMBL1599550 0.78 TACR1 (0.54) KCNH2SLC6A4HTR2ATMEM97TP53
SCHEMBL10050765 0.78 SLC6A4 (0.46) KCNH2SLC6A4HTR2AMEN1KMT2A
SCHEMBL4236215 0.78 KCNH2 (0.47) KCNH2SLC6A4HTR2ATMEM97TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137653-A1 SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE INFLAYZME PHARMACEUTICALS LTD. (CA) 2009-05-28 US disclosed
EP-1871357-A2 SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE Inflazyme Pharmaceuticals, Ltd. (CA) 2008-01-02 EP disclosed
WO-2006108149-A2 SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE INFLAZYME PHARMACEUTICALS LTD. (CA) 2006-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137653-A1 SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE CYP2A6, CYP2B6, CYP2D6 KCNH2 2633/4885SLC6A4 134/4885HTR2A 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.